Trevi Therapeutics (TRVI) Tops Q4 EPS by 2c

Trevi Therapeutics (NASDAQ: TRVI) reported Q4 EPS of ($0.28), $0.02 better than the analyst estimate of ($0.30).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• General Mills posts lower Q1 sales, reaffirms fiscal 2027 targets
• Oppenheimer Starts Viatris (VTRS) at Outperform